Alkermes

Incorporated in 1987, Alkermes is headquartered in Dublin, Ireland, and is primarily engaged in developing, manufacturing, and marketing pharmaceuticals for the treatment of central nervous system (CNS) diseases and addiction. Their focus areas include CNS diseases such as schizophrenia, depression, and bipolar disorder. Among their most prominent brands are VIVITROL®, an injectable medication for alcohol dependence and prevention of opioid dependence relapse; ARISTADA®, an extended-release injectable antipsychotic for schizophrenia; and ARISTADA INITIO®, which is used for initiating or re-initiating treatment for schizophrenia in adults. Alkermes operates mainly in the United States, which represents its most significant market, though its products are also available internationally through various distribution partnerships or direct sales in specific countries. The range of products that Alkermes offers may change over time due to the introduction of new pharmaceuticals or the discontinuation of older ones. (Powered by AI)